Literature DB >> 16012318

Tumor lesion detection: when is integrated positron emission tomography/computed tomography more accurate than side-by-side interpretation of positron emission tomography and computed tomography?

Ur Metser1, Orit Golan, Charles D Levine, Einat Even-Sapir.   

Abstract

OBJECTIVES: To determine if there is added value to oncology studies performed with a dedicated in-line positron emission tomography (PET)/computed tomography (CT) scanner as compared with PET read side by side with diagnostic CT (DCT).
METHODS: Forty-one consecutive oncology patients referred for PET/CT who had contemporary DCT scans for review were enrolled. Body regions assessed on a DCT scan were assessed on PET/CT and by side-by-side reading of PET and DCT (SBS PET/DCT). Lesions identified on DCT, the CT portion of PET/CT, SBS PET/DCT, and the reading of fused PET/CT images were scored as benign or malignant. The PET portion of the PET/CT study was read by 2 teams: the first read the SBS PET/DCT scan and the other read the complete fused PET/CT scan. For discordant lesions, the final diagnosis was determined by pathologic findings (n = 6) or imaging follow-up (n = 21).
RESULTS: Twenty-seven (16.1%) of the 168 lesions were discordant when comparing analysis of fused PET/CT and SBS PET/DCT. Sixteen (9.5%) were fundamentally discordant, and 11(6.6%) were discordant in degree of confidence. For all discordant lesions only, the sensitivity, specificity, negative predictive value, positive predictive value, and accuracy for PET/CT were 100%, 33%, 100%, 94%, and 78%, respectively, and for SBS PET/DCT, they were 38%, 50%, 19%, 73%, and 30%, respectively (P < 0.001 for sensitivity, P = not specific for specificity). The 2 main causes for misclassification on SBS PET/DCT were incorrect localization (n = 12) and changes occurring in the time gap between DCT and PET/CT (n = 4).
CONCLUSIONS: In-line PET/CT offers better lesion localization in comparison to the visual fusion of PET and CT, especially for small lymph nodes, lesions adjacent to mobile organs, or lesions adjacent to the chest or abdominal wall.

Entities:  

Mesh:

Year:  2005        PMID: 16012318     DOI: 10.1097/01.rct.0000164671.96143.c2

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  11 in total

1.  Utilisation of combined 18F-FDG PET/CT scan for differential diagnosis between benign and malignant adrenal enlargement.

Authors:  J Y Kim; S H Kim; H J Lee; M J Kim; Y H Kim; S H Cho; K S Won
Journal:  Br J Radiol       Date:  2013-07-05       Impact factor: 3.039

2.  Diagnostic accuracy of whole-body MRI/DWI image fusion for detection of malignant tumours: a comparison with PET/CT.

Authors:  Michael A Fischer; Daniel Nanz; Thomas Hany; Caecilia S Reiner; Paul Stolzmann; Olivio F Donati; Stefan Breitenstein; Paul Schneider; Dominik Weishaupt; Gustav K von Schulthess; Hans Scheffel
Journal:  Eur Radiol       Date:  2010-08-18       Impact factor: 5.315

3.  The current role of PET-CT in the characterization of hepatobiliary malignancies.

Authors:  Ginseppe Garcea; Seok Ling Ong; Guy J Maddern
Journal:  HPB (Oxford)       Date:  2009-02       Impact factor: 3.647

4.  The clinical impact of [(18)F]FDG PET/CT for the management of recurrent endometrial cancer: correlation with clinical and histological findings.

Authors:  Hyun Hoon Chung; Won Jun Kang; Jae Weon Kim; Noh-Hyun Park; Yong-Sang Song; June-Key Chung; Soon-Beom Kang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-08       Impact factor: 9.236

5.  The role of PET/CT in cervical cancer.

Authors:  Fernanda G Herrera; John O Prior
Journal:  Front Oncol       Date:  2013-02-26       Impact factor: 6.244

6.  Usefulness of the maximum standardized uptake value for the diagnosis and staging of patients with cervical cancer undergoing positron emission tomography/computed tomography.

Authors:  Hiroaki Takagi; Jinichi Sakamoto; Yasuhiro Osaka; Takeo Shibata; Satoko Fujita; Toshiyuki Sasagawa
Journal:  Medicine (Baltimore)       Date:  2018-02       Impact factor: 1.817

7.  [18F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial.

Authors:  Rachel M Glicksman; Ur Metser; John Valliant; Peter W Chung; Neil E Fleshner; Robert G Bristow; David Green; Antonio Finelli; Robert Hamilton; Teodor Stanescu; Douglas Hussey; Charles Catton; Mary Gospodarowicz; Padraig Warde; Andrew Bayley; Stephen Breen; Doug Vines; David A Jaffray; Alejando Berlin
Journal:  BMJ Open       Date:  2020-04-22       Impact factor: 2.692

8.  Case report: PET/CT, a cautionary tale.

Authors:  Jayson Wang; Gary Cook; John Frank; Roberto Dina; Naomi Livni; John Lynn; William Fleming; Michael J Seckl
Journal:  BMC Cancer       Date:  2007-08-03       Impact factor: 4.430

Review 9.  Multi-modality nuclear medicine imaging: artefacts, pitfalls and recommendations.

Authors:  Jorn A van Dalen; Wouter V Vogel; Frans H M Corstens; Wim J G Oyen
Journal:  Cancer Imaging       Date:  2007-05-28       Impact factor: 3.909

Review 10.  SPECT/CT in the Evaluation of Suspected Skeletal Pathology.

Authors:  Bhasker Rao Koppula; Kathryn A Morton; Ragheed Al-Dulaimi; Gabriel C Fine; Nikolas M Damme; Richard K J Brown
Journal:  Tomography       Date:  2021-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.